STOCK TITAN

Masimo to Present in the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Masimo (NASDAQ: MASI) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 8:30 a.m. Eastern time. Interested parties can access a live webcast of the presentation through the company's website at www.masimo.com. The company will also make a replay of the webcast available after the live presentation concludes.

Masimo (NASDAQ: MASI) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. La presentazione è fissata per martedì 3 dicembre 2024, alle 8:30 ora orientale. Le parti interessate possono accedere a una trasmissione in diretta della presentazione tramite il sito web dell'azienda all'indirizzo www.masimo.com. L'azienda renderà disponibile anche una registrazione della trasmissione dopo la conclusione della presentazione dal vivo.

Masimo (NASDAQ: MASI) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La presentación está programada para el martes 3 de diciembre de 2024 a las 8:30 a.m. hora del Este. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de la empresa en www.masimo.com. La empresa también ofrecerá una repetición de la transmisión después de que concluya la presentación en vivo.

Masimo (NASDAQ: MASI)Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 프레젠테이션은 2024년 12월 3일 화요일 동부 표준시 오전 8시 30분에 예정되어 있습니다. 관심 있는 분들은 www.masimo.com 웹사이트를 통해 프레젠테이션의 실시간 웹캐스트에 접속할 수 있습니다. 회사는 또한 라이브 프레젠테이션이 끝난 후 웹캐스트의 재생을 제공할 것입니다.

Masimo (NASDAQ: MASI) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. La présentation est prévue pour mardi 3 décembre 2024, à 8h30, heure de l'Est. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site web de l'entreprise à www.masimo.com. L'entreprise mettra également à disposition un enregistrement du webinaire après la conclusion de la présentation en direct.

Masimo (NASDAQ: MASI) hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Die Präsentation ist für Dienstag, den 3. Dezember 2024, um 8:30 Uhr Eastern Standard Time geplant. Interessierte können die live Übertragung der Präsentation über die Website des Unternehmens unter www.masimo.com abrufen. Das Unternehmen wird nach Abschluss der Live-Präsentation auch eine Wiederholung der Übertragung zur Verfügung stellen.

Positive
  • None.
Negative
  • None.

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 8:30 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and Masimo W1 Sport. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar.
  8. Estimate: Masimo data on file.
  9. https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation

Investor Contact: Eli Kammerman

(949) 297-7077

ekammerman@masimo.com

Media Contact: Evan Lamb

(949) 396-3376

elamb@masimo.com

Source: Masimo

FAQ

When is Masimo (MASI) presenting at the Piper Sandler Healthcare Conference 2024?

Masimo will present at the Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern time.

How can I watch Masimo's (MASI) presentation at the Piper Sandler Conference?

You can watch the live webcast of Masimo's presentation through their website at www.masimo.com. A replay will also be available after the presentation.

Will there be a replay available of Masimo's (MASI) Piper Sandler Conference presentation?

Yes, a replay of the webcast will be available on Masimo's website following the live presentation.

Which healthcare conference is Masimo (MASI) participating in December 2024?

Masimo is participating in the Piper Sandler 36th Annual Healthcare Conference in December 2024.

Masimo Corporation

NASDAQ:MASI

MASI Rankings

MASI Latest News

MASI Stock Data

9.15B
49.16M
8.19%
94.99%
5.98%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
IRVINE